Filing Flows › Bioventus (BVS) › Q3 2026 › vs Q2 2026
Bioventus (BVS) Q3 2026 vs Q2 2026 (quarter over quarter)
Bioventus's revenue fell $10.8M (-7%) from $153M in Q2 2026 to $142M in Q3 2026. Gross margin 68.2% against 69.0% (-0.8 pts).
Bioventus, Q3 2026: revenue $142M (+3% year over year), operating margin 6.8%, net earnings $6.0M, operating cash flow $20.7M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 68.2% | 69.0% | -0.8 pts |
| Operating margin | 6.8% | 12.5% | -5.7 pts |
| Net margin | 4.2% | 21.8% | -17.6 pts |
| Free cash flow margin | 14.3% | 12.3% | +1.9 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $142M | $153M | −$10.8M | -7% |
| Gross profit | $97.1M | $106M | −$8.5M | -8% |
| Cost of revenue | $45.3M | $47.5M | −$2.2M | -5% |
| Operating profit | $9.7M | $19.1M | −$9.4M | -49% |
| Operating expenses | $87.4M | $86.5M | $889K | +1% |
| Pre-tax earnings | $6.2M | $15.3M | −$9.2M | -60% |
| Other expense, net | $3.5M | $3.8M | −$277K | -7% |
| Research & development | $3.4M | $3.2M | $262K | +8% |
| SG&A | $82.9M | $82.7M | $205K | +0.2% |
| Other operating costs | $1.0M | $626K | $422K | +67% |
| Income tax benefit | $701K | $20.9M | −$20.2M | -97% |
| Net earnings | $6.0M | $33.4M | −$27.5M | -82% |
| Minority interests | $872K | $2.8M | −$1.9M | -68% |
| Depreciation & amortization | $10.3M | $10.9M | −$630K | -6% |
| Share-based compensation | $4.8M | $5.0M | −$285K | -6% |
| Working capital & other | $400K | $29.6M | −$29.2M | -99% |
| Operating cash flow | $20.7M | $19.9M | $785K | +4% |
| Free cash flow (OCF − capex) | $20.3M | $18.9M | $1.4M | +7% |
| Capital expenditures | $334K | $960K | −$626K | -65% |
Questions
How much did Bioventus's revenue grow quarter over quarter in Q3 2026?
Bioventus's revenue fell $10.8M (-7%) from $153M in Q2 2026 to $142M in Q3 2026. Gross margin 68.2% against 69.0% (-0.8 pts).